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Abstract
Introduction: In this study, we aimed to assess the association between acute kidney injury (AKI) and mortality in
critically ill patients using an original competing risks approach.
Methods: Unselected patients admitted between 1997 and 2009 to 13 French medical or surgical intensive care
units were included in this observational cohort study. AKI was defined according to the RIFLE criteria. The
following data were recorded: baseline characteristics, daily serum creatinine level, daily Sequential Organ Failure
Assessment (SOFA) score, vital status at hospital discharge and length of hospital stay. Patients were classified
according to the maximum RIFLE class reached during their ICU stay. The association of AKI with hospital mortality
with “discharge alive” considered as a competing event was assessed according to the Fine and Gray model.
Results: Of the 8,639 study patients, 32.9% had AKI, of whom 19.1% received renal replacement therapy. Patients
with AKI had higher crude mortality rates and longer lengths of hospital stay than patients without AKI. In the Fine
and Gray model, independent risk factors for hospital mortality were the RIFLE classes Risk (sub-hazard ratio (SHR)
1.58 and 95% confidence interval (95% CI) 1.32 to 1.88; P < 0.0001), Injury (SHR 3.99 and 95% CI 3.43 to 4.65; P <
0.0001) and Failure (SHR 4.12 and 95% CI 3.55 to 4.79; P < 0.0001); nonrenal SOFA score (SHR 1.19 per point and
95% CI 1.18 to 1.21; P < 0.0001); McCabe class 3 (SHR 2.71 and 95% CI 2.34 to 3.15; P < 0.0001); and respiratory
failure (SHR 3.08 and 95% CI 1.36 to 7.01; P < 0.01).
Conclusions: By using a competing risks approach, we confirm in this study that AKI affecting critically ill patients
is associated with increased in-hospital mortality.
Introduction
Acute renal failure (ARF) is as an abrupt decline in kid-
ney function. Although simple to define conceptually,
there has long been no consensus on an operational
definition of ARF. As reported in a recent survey, more
than 35 definitions have been used so far [1]. Depending
on the definition used, ARF has been shown to affect
from 1% to 25% of intensive care unit (ICU) patients
and has led to mortality rates from 15% to 60% [2].
Because the lack of a uniform definition is a major
impediment to epidemiological research in the field, the
Acute Dialysis Quality Initiative Group (ADQIG) [3]
recently proposed consensus definition criteria, namely,
the RIFLE criteria based on three grades of increasing
severity (Risk of renal dysfunction, Injury to the kidney,
and Failure of kidney function) and two outcome classes
( L o s so fk i d n e yf u n c t i o na n dE n d - s t a g ek i d n e yd i s e a s e )
(Table 1). Furthermore, they proposed that the old
nomenclature ARF be replaced by the term acute kidney
injury (AKI) to encompass the entire spectrum of the
syndrome, from minor changes in renal function to
need for renal replacement therapy (RRT).
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advance in that it allows easier comparisons across stu-
dies. Overall, it seems to correlate well with patients’
outcomes [4-9]. In the ICU setting, only four multiple-
center studies using the RIFLE criteria have been pub-
lished so far [10-13]. All but one [12] found AKI to be
associated with a poor outcome, with some residual het-
erogeneity regarding both incidence and mortality, how-
ever. In addition, estimates of AKI-associated mortality
in these studies derived from traditional logistic regres-
sion or Cox models, while concerns about their reliabil-
ity have been raised recently [14]. Briefly, logistic
regression analysis ignores the timing of events and
their chronological order, potentially leading to an over-
estimation of the association between a specific risk fac-
tor (for example, nosocomial pneumonia) and mortality
[15]. This problem can be solved to some extent by
applying the Cox model, which allows for the considera-
tion of time-dependent covariates. Yet, this model does
not deal with the competing risks issue. This issue arises
when more than one endpoint is possible [16]. Typically,
“dying in hospital” and “discharge alive” are two com-
peting risks. If “dying in hospital” is the event of inter-
est, the nonfatal competing event “discharge alive”
hinders the event of interest from occurring as a first
event.
Statistical models able to handle time-dependent cov-
ariates and allowing the simultaneous analysis of differ-
ent endpoints (that is, competing risks) are now
available [15,17-19]. In recent years, these models have
engendered growing interest in hospital epidemiology
(especially with regard to cancer research) but have
rarely been used in the ICU field.
T h ea i mo ft h i ss t u d yw a st of u r t h e ra s s e s st h ea s s o -
ciation between AKI defined by RIFLE criteria and in-
hospital mortality in critically ill patients by using such
an original competing risks approach.
Materials and methods
Study design and data source
We conducted an observational study in a multiple-cen-
ter database (OUTCOMEREA) from January 1997 to
June 2009. The methods of data collection and the
quality of the database have been described in detail
elsewhere [20]. Briefly, the database receives information
from 13 French ICUs. To avoid selection bias and
ensure external validity, a random sample of patients
older than 16 years of age and staying in the ICU for
>24 hours are entered into the database each year. Parti-
cipating centers can choose between two modes of
patient selection: (1) consecutive admissions in “n” ICU
beds for the whole year or (2) consecutive admissions in
a particular month. The allocation of beds (or a particu-
lar month) is decided yearly by the database’ss t e e r i n g
committee.
Data are prospectively collected on a daily basis by
senior physicians of the participating ICUs who are clo-
sely involved in establishing the database. For all patients,
information is recorded at baseline (including demo-
graphic characteristics, comorbidities, baseline severity,
admission diagnosis, admission category and transfer
from ward) and on each consecutive day throughout the
ICU stay (including diagnostic and therapeutic proce-
dures, biological parameters, organ failure, sepsis, occur-
rence of iatrogenic events and decision to withhold or
withdraw life-sustaining treatments). The quality control
procedure involves multiple automatic checking of inter-
nal consistency and biennial audits. Moreover, a one-day
data capture training course is held once yearly for all
OUTCOMEREA investigators and study monitors. OUT-
COMEREA senior physicians and participating centers
are listed in the Acknowledgements.
I na c c o r d a n c ew i t hF r e n c hl aw, the development and
maintenance of the OUTCOMEREA database were dis-
closed to the Commission Nationale de l’Informatique
et des Libertés. The study was approved by the ethics
committee of Clermont-Ferrand, France. Because rou-
tine collection of data entered into the database did not
modify patients’ management in any way, and because
statistical analyses were processed anonymously,
informed consent for participation in the study was
waived.
Study population and definitions
All patients in the database were eligible for inclusion in
the study. For patients who were admitted more than
Table 1 RIFLE classification
a
RIFLE class GFR criteria UO criteria
Risk Increase in serum creatinine ≥1.5 × baseline or decrease in GFR ≥25% <0.5 ml/kg/hour for ≥6 hours
Injury Increase in serum creatinine ≥2 × baseline or decrease in GFR ≥ 50% <0.5 ml/kg/hour for ≥12 hours
Failure Increase in serum creatinine ≥3 × baseline or decrease in GFR ≥75% or serum creatinine ≥350
μmol/L with an acute rise of at least 44 μmol/L
<0.3 ml/kg/hour for ≥24 hours or
anuria ≥12 hours
Loss Complete loss of kidney function >4 weeks
End-stage
kidney disease
Need for RRT >3 months
aGFR, glomerular filtration rate; UO, urine output; RRT, renal replacement therapy.
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the analysis. AKI was defined according to the RIFLE cri-
teria. Patients were classified according to the maximum
RIFLE class (no AKI, Risk, Injury or Failure) reached dur-
ing their ICU stay as described in previous reports
[10,11,13]. For patients who received RRT, the maximum
RIFLE class was that reached before RRT initiation. Since
the 6- and 12-hour urine outputs were not recorded in
the database, we used the glomerular filtration rate
(GFR) only. The GFR criteria were determined according
to changes in serum creatinine level from baseline values.
Because AKI may be present on ICU admission in a high
proportion of patients, we chose to assess baseline creati-
nine values using the Modification of Diet in Renal Dis-
ease (MDRD) equation. As recommended by the
ADQIG, a normal GFR of 75 ml/minute/1.73 m
2 before
ICU admission was assumed [3].
Patients with chronic kidney disease (assessed accord-
ing to the Acute Physiology and Chronic Health Evalua-
tion (APACHE) II definitions [21]) and patients with a
nonorganic (prerenal) cause of renal dysfunction (identi-
f i e db yas p e c i f i cc o d ei nt h ed a t a b a s e )w e r ee x c l u d e d
because their prognosis is potentially different (better)
from that of patients with “true” de novo organic AKI.
Patients put on RRT while no diagnosis of AKI had
been made (that is, patients with RRT for “extrarenal
indications” such as intoxications or cardiogenic shock)
were also excluded because it was impossible to deter-
mine whether AKI was not actually present or could not
be diagnosed thereafter as a consequence of the reduc-
tion in serum creatinine due to RRT. Finally, any deci-
sion to withhold or withdraw life-sustaining treatments
led to exclusion of patients from analysis to avoid bias-
ing the estimation of the association between AKI and
hospital mortality.
Data collection
The following data were recorded:
1. Upon ICU admission: patient age, sex, McCabe
class (class 1, no fatal underlying disease; class 2, under-
lying disease fatal within 5 years; class 3, underlying dis-
ease fatal within 1 year [22]) Simplified Acute
Physiology Score (SAPS) II, nonrenal Sequential Organ
Failure Assessment (SOFA) score (SOFA renal compo-
nent), comorbidities assessed according to the Acute
Physiology and Chronic Health Evaluation (APACHE) II
definitions, transfer from ward (defined as a stay in an
acute bed ward ≥24 hours immediately before ICU
admission) and admission category (medical, scheduled
surgery, or unscheduled surgery).
2. During the ICU stay: daily serum creatinine level,
time from admission to occurrence of AKI, time from
admission to the maximum RIFLE class and daily SOFA
score.
3. Upon ICU discharge: length of ICU stay.
4. Upon hospital discharge: length of hospital stay and
vital status.
Endpoints
The primary endpoint was hospital mortality. The sec-
ondary endpoints were the length of ICU stay and hos-
pital stay.
Statistical analyses
Comparisons of patients with and those without AKI
were based on c
2 tests for categorical data and on Stu-
dent’s t-test or Wilcoxon’s rank-sum test for continuous
data as appropriate. Comparisons of AKI patients
according to their maximum RIFLE class were based on
c
2 tests for categorical data and on one-way analysis of
variance or the Kruskal-Wallis test for continuous data
as appropriate.
The association of AKI with mortality was assessed
according to the Fine and Gray [23] subdistribution
hazard regression model, which extends the Cox model
to competing risk data by considering the hazard func-
tion associated with the cumulative incidence function
(CIF). The main advantage of the CIF and Fine and
Gray model over the Kaplan-Meier (KM) method and
Cox model pertains to censoring. Indeed, the KM
method and the Cox model assume that censoring is
uninformative (that is, that the survival time of an indi-
vidual is independent of censoring). Accordingly,
patients discharged alive at time t are considered to be
representative of all other patients who have survived to
this time t but who still have not been discharged. This
m a yb et r u ew h e nt h ec e n s o r i n gp r o c e s so p e r a t e sr a n -
domly. However, this assumption probably cannot be
made in the case of ICU patients. Actually, since these
patients are discharged alive (censored) because of an
improvement (or sometimes a deterioration) of their
medical state, they have a lower (or sometimes higher)
risk of dying than the average and are therefore not
representative of other patients who have not been cen-
sored yet. Thus, censoring is clearly informative (that is,
the survival time of an individual does depend on cen-
soring). In other words, informative censoring defines a
competing risk, given that discharge alive affects the
probability of experiencing the event of interest (death
before discharge). In this setting, standard survival
methods are no longer valid, and specific approaches,
such as the CIF and Fine and Gray model that allow
handling of both time to events and informative censor-
ing [24,25], merit consideration.
At time t, the CIF defines the probability of dying,
provided that the study population has survived at time
t -1. Contrary to a distribution function that tends
toward 1, the CIF tends to the raw proportion of deaths.
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strength of the association between a specific risk factor
and the event of interest in the Fine and Gray model is
reflected by the sub-hazard ratio (SHR), which is the
ratio of hazards associated with the CIF in the presence
and absence of the risk factor. Note that this model was
originally developed for time-independent risk factors
[23]. However, while cumulative incidence is no longer
available for time-dependent risk factors, cumulative
hazards may be considered instead and SHR can still be
computed [26].
We first computed SHR for mortality and 95% confi-
dence intervals associated with each of the Risk, Injury
and Failure classes in univariate analysis. Then we per-
formed a multivariate analysis to adjust for the following
predefined potential confounding factors: baseline char-
acteristics (nonrenal SOFA score, McCabe class, admis-
sion category and transfer from ward) and other organ
failures (assessed on the basis of a specific SOFA com-
ponent >2) occurring before AKI. To account for their
timing and chronological order [26], each RIFLE class
and organ failure were entered into the Fine and Gray
model as time-dependent variables (in other words, time
to organ failure and changes over time were implicitly
considered).
A P value < 0.05 was considered significant. Analyses
were computed using the SAS 9.1 software (SAS Insti-
tute, Cary, NC, USA) and the free R software package.
Results
Study population
Of the 10,911 patients in the OUTCOMEREA database,
2,272 (20.8%) had exclusion criteria. Among the remain-
ing 8,639 patients, 2,846 (32.9%) had AKI, of whom 545
(19%) received RRT (Figure 1).
Patients with AKI were older, had higher severity
scores, were more likely to have undergone unscheduled
surgery and had more severe comorbidities than patients
without AKI (Table 2). Among AKI patients, higher
severity scores and unscheduled surgery were associated
with a higher degree of renal dysfunction (Table 3).
Dynamics of AKI
AKI was a rapidly evolving process. Times from ICU
admission to occurrence of AKI (median days (inter-
quartile range)) were 1 (1 to 2), 2 (1 to 2) and 1 (1 to 2)
in the class R, I and F patients, respectively. Times from
ICU admission to maximum RIFLE class were 1 (1 to
2), 2 (1 to 3) and 2 (1 to 3) in R, I, and F patients,
respectively.
Figure 2 illustrates the lowest and highest degrees of
renal dysfunction reached during the ICU stay and the
proportion of patients displaying progressive alteration
of kidney function.
Impact of AKI on mortality
Overall, hospital mortality rates were higher in patients
with AKI than in those without AKI (27.6% vs. 8.7%; P
< 0.0001). Among AKI patients, I and F class patients
had higher mortality rates than R class patients (33.9%
and 33.5% vs. 16.7%, respectively; P < 0.0001).
The multivariate Fine and Gray model revealed that R,
I and F classes of the RIFLE criteria were independent
risk factors for in-hospital mortality (Table 4). Other
variables independently associated with in-hospital mor-
tality were nonrenal SOFA score, McCabe class 3 and
respiratory failure occurring before AKI onset (Table 4).
Impact of AKI on lengths of stays and need for prolonged
renal support
Patients with AKI had longer (median days (interquartile
r a n g e ) )I C Us t a y s( n oA K I :4( 3t o7 ) ,Rc l a s s :6( 3t o
11), I class: 7 (4 to 12) and F class: 8 (4 to 17), P <
0.001) and longer hospital stays (no AKI: 16 (9 to 30), R
class: 22 (12 to 40), I class: 21 (10 to 37) and F class: 25
(12 to 44); P < 0.001) than patients without AKI. Upon
ICU discharge, 92 survivors (3.2%) among the 2,846 AKI
patients still needed renal support.
Discussion
The association of AKI with critically ill patients’ out-
comes has been widely investigated, but very few multi-
ple-center evaluations using the RIFLE criteria have
been published so far [10-13]. Our study, carried out in
a large cohort of general ICU patients, supports the use
of RIFLE as a classification tool and confirms previous
evidence that AKI negatively influences patients’
outcomes.
Figure 1 Study flow chart. RRT, renal replacement therapy; R class,
Risk; I class, Injury; F class, Failure.
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a
Variable Patients with AKI (n = 2,846) Patients without AKI (n = 5,793) P value
Mean age, years (±SD) 66.4 (15.9) 55.6 (18.5) <0.0001
Males, n (%) 1,672 (58.8) 3,609 (62.3) 0.002
Mean SAPS II score (±SD) 50.2 (20.0) 33.6 (16.9) <0.0001
Mean APACHE II score (±SD) 19.9 (7.1) 12.9 (6.4) <0.0001
Mean non-renal SOFA score (±SD) 5.3 (3.2) 3.6 (2.7) <0.0001
Transfer from ward, n (%) 1363 (47.9) 2494 (43.1) <0.0001
McCabe class, n (%)
1 1,666 (58.5) 4,074 (70.3) <0.0001
2 959 (33.7) 1,417 (24.5)
3 221 (7.8) 302 (5.2)
Admission category, n (%)
Medical 2,043 (71.8) 4,149 (71.6) <0.0001
Scheduled surgery 311 (10.9) 865 (14.9)
Unscheduled surgery 492 (17.3) 779 (13.5)
Chronic coexisting conditions, n (%)
Cardiac disease 509 (17.9) 497(8.6) <0.0001
Respiratory disease 366 (12.9) 881 (15.2) 0.004
Liver disease 178 (6.3) 288 (5.0) 0.01
Immunodeficiency 440 (15.5) 688 (11.9) <0.0001
Uncomplicated diabetes mellitus 320 (11.2) 431 (7.4) <0.0001
Complicated diabetes mellitus 148 (5.2) 124 (2.1) <0.0001
aAKI, acute kidney injury; SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure
Assessment; nonrenal SOFA: SOFA renal component.
Table 3 Baseline characteristics of AKI patients according to the maximum RIFLE class reached during the intensive
care unit stay
a
Variable Class R patients (n = 1,025) Class I patients (n = 830) Class F patients (n = 991) P value
Mean age, years (±SD) 67.6 (15.8) 66.7 (15.7) 64.9 (16.0) <0.001
Males, n (%) 588 (57.4) 502 (60.5) 582 (58.7) 0.4
Mean SAPS II score (±SD) 45.2 (17.4) 51.9 (21.2) 53.8 (20.3) <0.0001
Mean APACHE II score (±SD) 18 (6.6) 20.6 (7.1) 21.4 (7.1) <0.0001
Mean non-renal SOFA score (±SD) 4.8 (3.1) 5.8 (3.3) 5.4 (3.4) <0.0001
Transfer from ward, n (%) 477 (46.5) 387 (46.6) 499 (50.4) 0.16
McCabe class, n (%)
1 608 (59.3) 476 (57.3) 582 (58.7) 0.8
2 342 (33.4) 290 (35.0) 327 (33)
3 75 (7.3) 64 (7.7) 82 (8.3)
Admission category, n (%)
Medical 754 (73.6) 592 (71.3) 697 (70.3) <0.002
Scheduled surgery 130 (12.7) 85 (10.2) 96 (9.7)
Unscheduled surgery 141 (13.8) 153 (18.4) 198 (20.0)
Chronic coexisting conditions, n (%)
Cardiac disease 185 (18.1) 163 (19.6) 161 (16.3) 0.2
Respiratory disease 165 (16.1) 101 (12.2) 100 (10.1) <0.001
Liver disease 61 (6.0) 59 (7.1) 58 (5.9) 0.5
Immunodeficiency 143 (14.0) 137 (16.5) 160 (16.2) 0.2
Uncomplicated diabetes mellitus 125 (12.2) 90 (10.8) 105 (10.6) 0.5
Complicated diabetes mellitus 45 (4.4) 40 (4.8) 63 (6.4) 0.1
aAKI, acute kidney injury; SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure
Assessment; non-renal SOFA: SOFA renal component.
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nal competing risks approach. This approach has many
potential advantages over the commonly used logistic
regression and Cox models. Actually, logistic regression
has been reported to cause loss of information because
it yields a time-independent probability of dying and
ignores the timing of events and their chronological
order [27,28]. While the Cox model may partially allevi-
ate these limits, it has been shown to overestimate the
incidence of the event of interest, with most of the over-
estimation being related to the rate of the competing
event [29]. By contrast, the Fine and Gray model ade-
quately addresses time spent in the hospital as a risk
factor for mortality by considering death hazard rates
and takes into account the time-varying exposure status,
thus avoiding a potential misjudgment in terms of time-
dependent bias [30,31]. Moreover, it provides a more
accurate estimation of mortality because death hazard
rates are not confounded by the competing event “dis-
charge alive.”
In keeping with the few similar multiple-center eva-
luations that have used the RIFLE criteria [10,11,13], we
found that AKI was an overall predictor of poor
outcomes (it must be noted, however, that results
regarding crude hospital mortality rates vary consider-
ably from one study to another, indicating residual het-
erogeneity despite the use of consensual definition
criteria) and that mortality differed according to the
maximum RIFLE class reached during the ICU stay. Of
note, even moderate renal dysfunction (R class)
impaired patients’ p r o g n o s i sa sp r e v i o u s l ys h o w n
[10,13,32], and, interestingly, the SHRs for I and F
classes were similar. These data suggest, similarly to the
study by Ostermann et al. [13], that the maximum risk
o fd e a t hm i g h tb er e a c h e da ss o o na sp a t i e n t sa r ei nI
class of the RIFLE criteria. Thus, therapeutic and pre-
ventive strategies, such as optimization of hemodynamic
parameters and avoidance of nephrotoxic drugs, must
undoubtedly be in order at an early stage of renal dys-
function to prevent further aggravation and to reduce
the risk of death.
Despite its strengths, our study has potential limita-
tions. First, the definition of AKI was not based on the
most recent consensus criteria proposed by the Acute
Kidney Injury Network (AKIN) group [33]. The main
differences between the AKIN and RIFLE classifications
are as follows: a smaller change in serum creatinine
level (>26.2 μmol/L) used to identify patients with stage
1 AKI (analogous to the RIFLE Risk class), a time con-
straint of 48 hours for the diagnosis of AKI and any
patient receiving RRT classified as having stage 3 AKI.
However, compared to the RIFLE criteria, there is cur-
rently no evidence that the AKIN criteria improve the
sensitivity, robustness and predictive ability of the defi-
nition and classification of AKI in the ICU [34-36]. This
is consistent with our finding that maximum renal dys-
function during the ICU stay was reached within a two-
day period in most patients. Furthermore, classifying
any patient receiving RRT in stage 3 is questionable and
may introduce bias because of the lack of uniform
recommendations regarding the timing and modalities
of RRT.
Second, assessing baseline creatinine values by the
MDRD equation as in previous reports may have
exposed our study methodology to the risk of inclusion
Figure 2 Dynamics of acute kidney injury (AKI) during
intensive care unit (ICU) stay. The flowchart illustrates the lowest
and highest degrees of renal dysfunction reached during the ICU
stay and the proportion of patients displaying progressive alteration
of kidney function.
Table 4 Association of AKI with hospital mortality: results of the unadjusted and adjusted Fine and Gray models
a
Variable SHR univariate analysis (95% CI) P value SHR multivariate analysis (95% CI) P value
No AKI 1 - 1 -
R class 2.28 (1.62 to 3.19) <0.0001 1.58 (1.32 to 1.88) <0.0001
I class 7.39 (5.37 to 10.17) <0.0001 3.99 (3.43 to 4.65) <0.0001
F class 9.73 (8.16 to 11.60) <0.0001 4.12 (3.55 to 4.79) <0.0001
Non-renal SOFA score, per point - - 1.19 (1.1.18 to 1.21) <0.0001
McCabe class 3 - - 2.71 (2.34 to 3.15) <0.0001
Respiratory failure - - 3.08 (1.36 to 7.01) <0.01
aSHR, sub-hazard ratio; 95% CI, 95% confidence interval; SOFA, Sequential Organ Failure Assessment; non-renal SOFA: SOFA renal component.
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the APACHE II definitions as having end-stage renal
disease or RRT dependence. This is a potential source
of misclassification bias [37] and underestimation of the
association between AKI and hospital mortality. This
issue needs further investigation.
Third, we encountered the same problem as others
did [9,13]: the 6- and 12-hour urine outputs were not
recorded in our database. Therefore, patients were clas-
sified according to the GFR criteria only. Patients classi-
fied according the GFR criteria seem to be more
severely ill and have slightly higher mortality rates than
their counterparts classified according to the urine out-
put criteria [11,38,39]. Consideration of both criteria
m a yh a v er e s u l t e di nal o w e s testimation of the risk of
death (and, conversely, a higher incidence of AKI).
Fourth, the potential confusing role of RRT was not
evaluated. However, the extent to which RRT interferes
with AKI patients’ prognosis remains unclear, and prac-
tices regarding this technique vary widely from one
institution to another. Consequently, considering RRT
as a confounder could have led to hazardous conclu-
sions. This issue deserves further specific evaluation.
Fifth, although it is multicentered, our database is not
multinational. So, our population may not be represen-
tative of ICU patients in other countries. Nevertheless,
the baseline characteristics, AKI incidence and propor-
tion of patients receiving RRT were similar to those
reported in previous studies [11,13].
Finally, we did not have any information as to the
exact etiology of AKI, although sepsis was probably the
commonest one. Of note, a recent study revealed that
RIFLE classification can be used to evaluate the overall
prognosis of septic patients, suggesting a close link
between AKI and sepsis [40]. However, AKI often
results from a combination of several risk factors whose
respective contributions are difficult to determine.
Whether any of these risk factors plays a preponderant
role (or whether patients’ prognosis differs according to
the cause of AKI) remains unknown.
Conclusions
While the prognosis for patients with AKI has long
remained unclear because of the lack of a uniform defi-
nition, the recently published RIFLE criteria have facili-
tated epidemiological research in the field. Three
multiple-center studies usingc o n v e n t i o n a ls t a t i s t i c a l
models found an association between RIFLE class and
mortality [10,11,13]. Original competing risks models
reflecting “real life” more accurately are now available
but are rarely used in the ICU setting. By applying such
a model, this study confirms that AKI affecting critically
ill patients is associated with increased mortality. How-
ever, further investigations focusing on the potential
confusing role of RRT are warranted to better character-
ize the prognosis of AKI patients.
Key messages
￿ The association of AKI with critically ill patients’
outcomes has been widely investigated, but very few
multiple-center evaluations using recent consensus
definition criteria have been published so far. Our
study, carried out on a large cohort of general ICU
patients, supports the use of RIFLE as a classification
tool and adds to the current limited evidence that
AKI negatively influences patients’ outcomes.
￿ By applying an original competing risks approach
and considering AKI as a time-dependent variable,
we likely provided a refined estimation of the asso-
ciation between AKI and mortality as compared to
previous reports.
￿ Further investigations focusing on the potential
confusing role of RRT are warranted to better char-
acterize the prognosis of AKI.
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